Cargando…
Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
BACKGROUND: Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking. METHODS: We did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults recruited between May 1 and November 2, 2020, without a pos...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860623/ https://www.ncbi.nlm.nih.gov/pubmed/35189888 http://dx.doi.org/10.1186/s12916-022-02286-4 |
_version_ | 1784654717350051840 |
---|---|
author | Talaei, Mohammad Faustini, Sian Holt, Hayley Jolliffe, David A. Vivaldi, Giulia Greenig, Matthew Perdek, Natalia Maltby, Sheena Bigogno, Carola M. Symons, Jane Davies, Gwyneth A. Lyons, Ronan A. Griffiths, Christopher J. Kee, Frank Sheikh, Aziz Richter, Alex G. Shaheen, Seif O. Martineau, Adrian R. |
author_facet | Talaei, Mohammad Faustini, Sian Holt, Hayley Jolliffe, David A. Vivaldi, Giulia Greenig, Matthew Perdek, Natalia Maltby, Sheena Bigogno, Carola M. Symons, Jane Davies, Gwyneth A. Lyons, Ronan A. Griffiths, Christopher J. Kee, Frank Sheikh, Aziz Richter, Alex G. Shaheen, Seif O. Martineau, Adrian R. |
author_sort | Talaei, Mohammad |
collection | PubMed |
description | BACKGROUND: Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking. METHODS: We did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults recruited between May 1 and November 2, 2020, without a positive swab test result for SARS-CoV-2 prior to enrolment. Information on 88 potential sociodemographic, behavioural, nutritional, clinical and pharmacological risk factors was obtained through online questionnaires, and combined IgG/IgA/IgM responses to SARS-CoV-2 spike glycoprotein were determined in dried blood spots obtained between November 6, 2020, and April 18, 2021. We used logistic and linear regression to estimate adjusted odds ratios (aORs) and adjusted geometric mean ratios (aGMRs) for potential determinants of SARS-CoV-2 seropositivity (all participants) and antibody titres (seropositive participants only), respectively. RESULTS: Of 11,130 participants, 1696 (15.2%) were seropositive. Factors independently associated with higher risk of SARS-CoV-2 seropositivity included frontline health/care occupation (aOR 1.86, 95% CI 1.48–2.33), international travel (1.20, 1.07–1.35), number of visits to shops and other indoor public places (≥ 5 vs. 0/week: 1.29, 1.06–1.57, P-trend = 0.01), body mass index (BMI) ≥ 25 vs. < 25 kg/m(2) (1.24, 1.11–1.39), South Asian vs. White ethnicity (1.65, 1.10–2.49) and alcohol consumption ≥15 vs. 0 units/week (1.23, 1.04–1.46). Light physical exercise associated with lower risk (0.80, 0.70–0.93, for ≥ 10 vs. 0–4 h/week). Among seropositive participants, higher titres of anti-Spike antibodies associated with factors including BMI ≥ 30 vs. < 25 kg/m(2) (aGMR 1.10, 1.02–1.19), South Asian vs. White ethnicity (1.22, 1.04–1.44), frontline health/care occupation (1.24, 95% CI 1.11–1.39), international travel (1.11, 1.05–1.16) and number of visits to shops and other indoor public places (≥ 5 vs. 0/week: 1.12, 1.02–1.23, P-trend = 0.01); these associations were not substantially attenuated by adjustment for COVID-19 disease severity. CONCLUSIONS: Higher alcohol consumption and lower light physical exercise represent new modifiable risk factors for SARS-CoV-2 infection. Recognised associations between South Asian ethnic origin and obesity and higher risk of SARS-CoV-2 seropositivity were independent of other sociodemographic, behavioural, nutritional, clinical, and pharmacological factors investigated. Among seropositive participants, higher titres of anti-Spike antibodies in people of South Asian ancestry and in obese people were not explained by greater COVID-19 disease severity in these groups. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02286-4. |
format | Online Article Text |
id | pubmed-8860623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88606232022-02-22 Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) Talaei, Mohammad Faustini, Sian Holt, Hayley Jolliffe, David A. Vivaldi, Giulia Greenig, Matthew Perdek, Natalia Maltby, Sheena Bigogno, Carola M. Symons, Jane Davies, Gwyneth A. Lyons, Ronan A. Griffiths, Christopher J. Kee, Frank Sheikh, Aziz Richter, Alex G. Shaheen, Seif O. Martineau, Adrian R. BMC Med Research Article BACKGROUND: Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking. METHODS: We did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults recruited between May 1 and November 2, 2020, without a positive swab test result for SARS-CoV-2 prior to enrolment. Information on 88 potential sociodemographic, behavioural, nutritional, clinical and pharmacological risk factors was obtained through online questionnaires, and combined IgG/IgA/IgM responses to SARS-CoV-2 spike glycoprotein were determined in dried blood spots obtained between November 6, 2020, and April 18, 2021. We used logistic and linear regression to estimate adjusted odds ratios (aORs) and adjusted geometric mean ratios (aGMRs) for potential determinants of SARS-CoV-2 seropositivity (all participants) and antibody titres (seropositive participants only), respectively. RESULTS: Of 11,130 participants, 1696 (15.2%) were seropositive. Factors independently associated with higher risk of SARS-CoV-2 seropositivity included frontline health/care occupation (aOR 1.86, 95% CI 1.48–2.33), international travel (1.20, 1.07–1.35), number of visits to shops and other indoor public places (≥ 5 vs. 0/week: 1.29, 1.06–1.57, P-trend = 0.01), body mass index (BMI) ≥ 25 vs. < 25 kg/m(2) (1.24, 1.11–1.39), South Asian vs. White ethnicity (1.65, 1.10–2.49) and alcohol consumption ≥15 vs. 0 units/week (1.23, 1.04–1.46). Light physical exercise associated with lower risk (0.80, 0.70–0.93, for ≥ 10 vs. 0–4 h/week). Among seropositive participants, higher titres of anti-Spike antibodies associated with factors including BMI ≥ 30 vs. < 25 kg/m(2) (aGMR 1.10, 1.02–1.19), South Asian vs. White ethnicity (1.22, 1.04–1.44), frontline health/care occupation (1.24, 95% CI 1.11–1.39), international travel (1.11, 1.05–1.16) and number of visits to shops and other indoor public places (≥ 5 vs. 0/week: 1.12, 1.02–1.23, P-trend = 0.01); these associations were not substantially attenuated by adjustment for COVID-19 disease severity. CONCLUSIONS: Higher alcohol consumption and lower light physical exercise represent new modifiable risk factors for SARS-CoV-2 infection. Recognised associations between South Asian ethnic origin and obesity and higher risk of SARS-CoV-2 seropositivity were independent of other sociodemographic, behavioural, nutritional, clinical, and pharmacological factors investigated. Among seropositive participants, higher titres of anti-Spike antibodies in people of South Asian ancestry and in obese people were not explained by greater COVID-19 disease severity in these groups. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02286-4. BioMed Central 2022-02-22 /pmc/articles/PMC8860623/ /pubmed/35189888 http://dx.doi.org/10.1186/s12916-022-02286-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Talaei, Mohammad Faustini, Sian Holt, Hayley Jolliffe, David A. Vivaldi, Giulia Greenig, Matthew Perdek, Natalia Maltby, Sheena Bigogno, Carola M. Symons, Jane Davies, Gwyneth A. Lyons, Ronan A. Griffiths, Christopher J. Kee, Frank Sheikh, Aziz Richter, Alex G. Shaheen, Seif O. Martineau, Adrian R. Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) |
title | Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) |
title_full | Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) |
title_fullStr | Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) |
title_full_unstemmed | Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) |
title_short | Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) |
title_sort | determinants of pre-vaccination antibody responses to sars-cov-2: a population-based longitudinal study (covidence uk) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860623/ https://www.ncbi.nlm.nih.gov/pubmed/35189888 http://dx.doi.org/10.1186/s12916-022-02286-4 |
work_keys_str_mv | AT talaeimohammad determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT faustinisian determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT holthayley determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT jolliffedavida determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT vivaldigiulia determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT greenigmatthew determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT perdeknatalia determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT maltbysheena determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT bigognocarolam determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT symonsjane determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT daviesgwynetha determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT lyonsronana determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT griffithschristopherj determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT keefrank determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT sheikhaziz determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT richteralexg determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT shaheenseifo determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk AT martineauadrianr determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk |